Results 1 to 10 of about 2,976 (190)

Role of HER2neu expression in gastric cancer

open access: yesIndian Journal of Pathology and Microbiology, 2021
Background: Gastric cancer is one of the most common cancers in the world and is responsible for over a million deaths. Gastric cancer broadly consists of two main histological types, diffuse and intestinal, and can be further classified as proximal ...
J S Sukanya   +2 more
doaj   +3 more sources

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers [PDF]

open access: yesBMC Research Notes, 2018
Objective Her2neu receptor is proto-oncogene which can be over-expressed in both luminal and non-luminal breast cancers. In the present study, we aimed to compare the prognostic and predictive factors like tumor grade, T-stage, N-stage and ki67 index in ...
Atif Ali Hashmi   +9 more
doaj   +3 more sources

Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore [PDF]

open access: yesBMC Cancer, 2011
Background Trastuzumab has revolutionized the way we treat early Her2Neu-positive breast cancer, as it significantly improves disease-free and overall survival.
Gilberto de Lima Lopes
core   +5 more sources

Trichorhinophalangeal syndrome type 1 (TRPS1) in breast pathology: diagnostic utility and pitfalls [PDF]

open access: yesDiagnostic Pathology
Introduction Breast cancer, especially triple-negative breast cancer (TNBC), lacks sensitive and specific diagnostic markers that can reliably differentiate it from carcinomas of other origins.
Atif Ali Hashmi   +2 more
doaj   +2 more sources

Targeted therapies in primary vaginal cancer [PDF]

open access: yesJournal of Cancer Research and Clinical Oncology
Objective Primary vaginal cancer (PVC) accounts for 1–2% of all gynecological malignancies. Therefore, clinical trials lack and there is a paucity of approved medications beyond radiation or chemoradiation as main first line therapy.
Laura Tascón Padrón   +7 more
doaj   +2 more sources

[Neuroendocrine expression markers in triple-negative, luminal-A, luminal-B and HER2neu breast cancer]. [PDF]

open access: yesRev Med Inst Mex Seguro Soc, 2023
Primary breast tumors with neuroendocrine (NE) differentiation are a heterogeneous tumor group with diversity of biological behavior, with poorly defined prevalence and prognosis.To evaluate the chromogranin, synaptophysin, CD56, INSM1 markers expression prevalence and the association between NE differentiation and tumor molecular type.Observational ...
Barboza-García YG   +4 more
europepmc   +4 more sources

The significance of expression of Her2neu in squamous cell carcinoma of uterine cervix [PDF]

open access: yesInternational Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2019
Background: Cervical cancer is one of the leading causes of cancer related deaths among females. It arises from precursor lesions i.e. squamous intraepithelial lesions which are closely associated with infection by HPV.
Sarin, Namrata   +3 more
core   +3 more sources

Clinicopathological Significance and Prognostic Role of Her2neu Protein Expression in Patients with Carcinoma Stomach: A Prospective Study from Northern India [PDF]

open access: yesSouth Asian Journal of Cancer, 2023
Abhilash V. B.   +4 more
doaj   +2 more sources

Human Leukocyte Antigen Class I Expression and Natural Killer Cell Infiltration and Its Correlation with Prognostic Features in Luminal Breast Cancers [PDF]

open access: yesBreast Cancer: Targets and Therapy
Maria Vernet-Tomas,1,2 Ivonne Vazquez,1,3 Francesc Olivares,3 David Lopez,3 Jose Yelamos,2,4 Laura Comerma1– 3 1Breast Diseases Unit, Hospital Del Mar, Barcelona, Spain; 2Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM ...
Vernet-Tomas M   +5 more
doaj   +2 more sources

Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer [PDF]

open access: yes, 2012
Introduction The presence of circulating tumor cells (CTC) is an independent prognostic factor for progression-free survival and breast cancer-related death (BRD) for patients with metastatic breast cancer beginning a new line of systemic therapy.
Arjan GJ Tibbe   +6 more
core   +23 more sources

Home - About - Disclaimer - Privacy